Publications by authors named "M P Maurelli"
Article Synopsis
- Cystic echinococcosis (CE) is a neglected tropical disease found in Italy, primarily affecting wild boars and dogs, and poses a risk to rural populations and outdoor enthusiasts.
- A study was conducted involving 122 wild boar hunters from southern Italy, which included blood sampling and questionnaires to assess their knowledge about the infection risk related to CE.
- Results showed that 4.9% of hunters had exposure to CE, 6.3% of hunting dogs tested positive for Taeniidae eggs, and the findings indicate the need for better education and health monitoring to reduce infection rates among hunters and their dogs.
Article Synopsis
- * In a study with 85 adults, 49.4% of patients showed at least a 90% improvement in eczema severity, while 61.2% had a favorable assessment from doctors.
- * No major safety issues were reported, and naïve patients (those who hadn't previously tried treatment) had better outcomes than those who had failed another medication, highlighting its effectiveness in real-world settings.
In the field of veterinary medicine, the detection of parasite eggs in the fecal samples of livestock animals represents one of the most challenging tasks, since their spread and diffusion may lead to severe clinical disease. Nowadays, the scanning procedure is typically performed by physicians with professional microscopes and requires a significant amount of time, domain knowledge, and resources. The Kubic FLOTAC Microscope (KFM) is a compact, low-cost, portable digital microscope that can autonomously analyze fecal specimens for parasites and hosts in both field and laboratory settings.
View Article and Find Full Text PDFCost per responder analysis of abrocitinib versus dupilumab in moderate to severe atopic dermatitis.
Ital J Dermatol Venerol
September 2024
Background: The JADE COMPARE was a multicenter, phase 3 randomized, double-blind, placebo-controlled trial with the objective of comparing the 16-week efficacy and safety of oral abrocitinib 100 or 200 mg once daily, dupilumab 300 mg subcutaneous injection every 2 weeks, or placebo in adults with moderate-to-severe atopic dermatitis (AD). Pharmacoeconomic evaluation of these new drugs for AD is lacking. The objective of our study was to compare the cost per responder of abrocitinib versus dupilumab in patients with AD using the data from the JADE COMPARE trial.
View Article and Find Full Text PDF